In a leap toward transforming cancer screening and detection globally, Cambridge-based biotechnology firm Harbinger Health, specializing in cancer screening and detection, successfully secured $140 million in Series B funding. Investors, including Flagship Pioneering, Pictet, Partners Investment, and Catalyst, led the funding round.
Under the leadership of CEO Stephen Hahn, M.D., Harbinger Health pioneers early cancer detection and introduces innovative methods in screening, diagnosis, and management. Their proprietary two-tier testing model, supported by cutting-edge technology and artificial intelligence, aims to offer low-cost population testing, significantly improving Positive Predictive Value (PPV) and enabling individualized longitudinal monitoring.
Funding for Progress, the Series B Investment
The funding, secured after foundational research in Flagship Pioneering’s Labs unit, provides Harbinger Health with the vital resources to achieve crucial milestones. The $140 million infusion will support completing Harbinger’s Cancer ORigin Epigenetics-Harbinger Health (CORE-HH) clinical study, encompassing 10,000 participants.
Additionally, it will fuel the development of their two-tier testing model, expand data science capabilities, and initiate vital clinical studies within high-risk populations.
HarbingerHx, its platform, utilizes machine learning and proprietary insights into cancer’s molecular origins, along with expanding datasets, to maximize clinical informativeness. Integrating advanced technology and vast datasets aims to render cancer screening an everyday health practice rather than a life-altering event.
A Glimpse into Tomorrow, Launching in 2025
Anticipated to debut in 2025, Harbinger Health’s first product, a laboratory-developed test (LDT) for early cancer detection, represents a significant leap forward. This LDT, in conjunction with the HarbingerHx platform and the company’s proprietary DNA library archiving technology, paves the way for the rapid development of additional products tailored to specific diseases and population groups.
Harbinger Health’s recent funding success signifies a step toward revolutionizing cancer screening. With a visionary approach, pioneering technology, and significant financial backing, the biotechnology company aims for an early cancer detection routine that is affordable and accessible on a global scale. As the world eagerly awaits Harbinger Health’s impactful contributions to healthcare, the future of cancer screening looks brighter.
Follow USTechTimes on Facebook, Twitter and Linkedin for in-depth news of market trends, funding updates, and regulatory changes affecting startups in USA.
We Recommend:
- Closing the gap, Herself Health raises $26M to provide personalized care for women 65+
- Vivante Health Secures $31 Million in Series B Funding to Revolutionize GI Care
- Imbue’s $200 Million Series B Funding Propels Valuation to $1 Billion
- Charm Industrial raises $100M to fuel carbon removal revolution
- Nashville-based Monogram Health bags milestone funding of $375 million
